logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Anemia In Chronic Kidney Disease

    FiltersReset Filters
    3 results

    • jesduvroq

      (daprodustat)
      GlaxoSmithKline LLC
      Usage: JESDUVROQ is indicated for treating anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months. It is not a substitute for red blood cell transfusions and is not indicated for non-dialysis CKD patients. No evidence of improved quality of life or fatigue.

    • retacrit

      (epoetin alfa-epbx)
      Pfizer Laboratories Div Pfizer Inc
      Usage: RETACRIT is indicated for treating anemia due to chronic kidney disease, zidovudine in HIV patients, chemotherapy in cancer patients, and to reduce RBC transfusions in high-risk surgical patients. It is not intended for patients treated with certain cancer therapies or those undergoing specific types of surgery.

    • vafseo

      (Vadadustat)
      Akebia Therapeutics, Inc.
      Usage: VAFSEO is indicated for anemia treatment in adults with chronic kidney disease (CKD) who have undergone dialysis for at least three months. It is not intended to improve quality of life or replace blood transfusions for immediate anemia correction, nor for CKD-related anemia in non-dialysis patients.